Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant Inc (NQ: IMVT )

27.75 -1.05 (-3.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,265,630
Open 28.21
Bid (Size) 25.00 (1)
Ask (Size) 28.35 (2)
Prev. Close 28.80
Today's Range 27.44 - 28.52
52wk Range 15.90 - 45.58
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Some of the market’s favorite biotech stocks have created immense wealth, as evidenced with the recent weight-loss drug stock boom. 
Via InvestorPlace
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart. 
Via Investor's Business Daily

Performance

YTD
-32.95%
-32.95%
1 Month
-11.11%
-11.11%
3 Month
-28.18%
-28.18%
6 Month
-18.27%
-18.27%
1 Year
+71.61%
+71.61%

More News

Read More
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
3 Under-the-Radar Biotech Stocks With Upcoming Catalysts in 2024
Via InvestorPlace
Recap: Immunovant Q3 Earnings
Via Benzinga
Argenx Dives On Autoimmune Therapy Failure
Via Investor's Business Daily
Analyst Ratings for Immunovant
Via Benzinga
Where Immunovant Stands With Analysts
Via Benzinga
Recap: Immunovant Q2 Earnings
Via Benzinga
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Via InvestorPlace
3 Top-Rated Russell 2000 Stocks Wall Street Analysts Are Loving Now: January 2024
Via InvestorPlace
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
Via The Motley Fool
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Via Investor's Business Daily
The Latest Analyst Ratings for Immunovant
Via Benzinga
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off
Via Investor's Business Daily
Autoimmune Disease Player Immunovant's Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Via Benzinga
Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
From Roivant Sciences
Via GlobeNewswire
Why Steelcase Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
From Roivant Sciences
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.